242 related articles for article (PubMed ID: 17306443)
21. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
23. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.
Gross M; Top I; Laux I; Katz J; Curran J; Tindell C; Agus D
Clin Cancer Res; 2007 Apr; 13(7):1979-86. PubMed ID: 17404077
[TBL] [Abstract][Full Text] [Related]
24. Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase.
Shao C; Wang Y; Yue HH; Zhang YT; Shi CH; Liu F; Bao TY; Yang ZY; Yuan JL; Shao GX
J Androl; 2007; 28(6):804-12. PubMed ID: 17581945
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer.
Halvorsen OJ; Rostad K; Øyan AM; Puntervoll H; Bø TH; Stordrange L; Olsen S; Haukaas SA; Hood L; Jonassen I; Kalland KH; Akslen LA
Clin Cancer Res; 2007 Feb; 13(3):892-7. PubMed ID: 17289882
[TBL] [Abstract][Full Text] [Related]
26. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.
Bjartell A; Johansson R; Björk T; Gadaleanu V; Lundwall A; Lilja H; Kjeldsen L; Udby L
Prostate; 2006 May; 66(6):591-603. PubMed ID: 16388501
[TBL] [Abstract][Full Text] [Related]
28. Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft.
Glasscock LN; Réhault SM; Gregory CW; Cooper ST; Jackson TP; Hoffman M; Church FC
Exp Mol Pathol; 2005 Aug; 79(1):23-32. PubMed ID: 15878512
[TBL] [Abstract][Full Text] [Related]
29. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.
Seligson DB; Hongo F; Huerta-Yepez S; Mizutani Y; Miki T; Yu H; Horvath S; Chia D; Goodglick L; Bonavida B
Clin Cancer Res; 2007 Oct; 13(20):6056-63. PubMed ID: 17947468
[TBL] [Abstract][Full Text] [Related]
30. Reverse transcriptase-polymerase chain reaction and immunohistochemical studies for detection of prostate stem cell antigen expression in prostate cancer: potential value in molecular staging of prostate cancer.
Joung JY; Yang SO; Jeong IG; Han KS; Seo HK; Chung J; Park WS; Lee KH
Int J Urol; 2007 Jul; 14(7):635-43. PubMed ID: 17645609
[TBL] [Abstract][Full Text] [Related]
31. Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:Cholesterol Acyltransferase (ACAT).
Locke JA; Wasan KM; Nelson CC; Guns ES; Leon CG
Prostate; 2008 Jan; 68(1):20-33. PubMed ID: 18000807
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.
Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R
Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561
[TBL] [Abstract][Full Text] [Related]
33. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
34. Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells.
Gouyer V; Fontaine D; Dumont P; de Wever O; Fontayne-Devaud H; Leteurtre E; Truant S; Delacour D; Drobecq H; Kerckaert JP; de Launoit Y; Bracke M; Gespach C; Desseyn JL; Huet G
Oncogene; 2008 Jul; 27(29):4024-33. PubMed ID: 18317448
[TBL] [Abstract][Full Text] [Related]
35. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB
Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366
[TBL] [Abstract][Full Text] [Related]
36. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract][Full Text] [Related]
37. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
[TBL] [Abstract][Full Text] [Related]
38. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
39. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer.
Ho LL; Kench JG; Handelsman DJ; Scheffer GL; Stricker PD; Grygiel JG; Sutherland RL; Henshall SM; Allen JD; Horvath LG
Prostate; 2008 Sep; 68(13):1421-9. PubMed ID: 18615486
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Lòpez Beltran A; Cheng L; Montorsi F; Scarpelli M
Eur Urol; 2007 Dec; 52(6):1682-9. PubMed ID: 17368711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
